-
Assessment of Pharmacokinetic/Pharmacodynamic Relationships through 48
Weeks from a Study
in HIV+,
ART-naive Subjects Receiving Antiretroviral Regimens Containing Atazanavir
400 mg or
Atazanavir/Ritonavir 300/100 mg Once Daily
R Bertz, Y Wang, L Mahnke, et al
Abstract
-
The
PACTG 1020A Protocol: Atazanavir with or without Ritonavir in HIV-infected
Infants, Children,
and
Adolescents
R Rutstein,
P Samson, J Kiser, et al
Abstract
-
Effect
of Rifampin on Pharmacokinetics and Safety of Twice-daily Atazanavir: ACTG
Protocol A5213
E Acosta, M
Kendall, J Gerber, et al
Abstract
-
Effect
of Famotidine 20- and 40-mg Dosing Regimens on the Bioavailability of
Atazanavir with Ritonavir
in
Combination with Tenofovir in Healthy Subjects
S Agarwala, A Persson, T Eley, et al
Abstract
-
Atazanavir Use in Pregnancy: A Report of 33 Cases
M Natha, P Hay, G Taylor, et al
Abstract
-
Effects
of Atazanavir or Saquinavir Once Daily with Ritonavir 100 mg and
Tenofovir/Emtricitabine as
Initial
Therapy for HIV-1 Infection on Peripheral Glucose Disposal: A Randomized
Open-label Study
A Jackson, N
Patel, G Lo, et al
Abstract
-
POSTER
Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir,
Darunavir, Lopinavir, and Tipranavir of
HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort
D Desbois, G Peytavin,
S Matheron, et al
PDF Poster
Abstract
-
POSTER
Atazanavir-based HAART in Pregnancy
D Ripamonti, D
Cattaneo, M Airoldi, et al
PDF
Poster
Abstract
-
POSTER
Body Composition
Changes in ART-naive Subjects Treated with Atazanavir or
Atazanavir/Ritonavir-
based Once-daily HAART: 48-Week Computed Tomography and DEXA Data
D McGrath, D
Frederick, V Wirtz, et al
PDF Poster
Abstract
- POSTER
Gilbert’s Disease
and Atazanavir: From Phenotype to UDP-glucuronosyltransferease Haplotype
T Lankisch, G Behrens, U Moebius, et al
PDF Poster
Abstract
|